R01TW012402
Project Grant
Overview
Grant Description
RCT of an Intersectional Stigma Intervention to Sustain Viral Suppression Among Women Living with Serious Mental Illness and HIV in Botswana - Abstract.
Reducing stigma to ensure viral load (VL) suppression for women with serious mental illness (SMI) and HIV is a global priority, including in Botswana, where the intersectional stigma of SMI, HIV, and womanhood is marginalizing in ways that impede adherence to both psychiatric medications and antiretroviral therapy (ART), which can threaten VL suppression.
We apply our novel 'What Matters Most' (WMM) approach to target intersectional stigma faced by women with SMI and HIV in Botswana via a stigma-reduction intervention in the high-risk transition period after discharge from an initial psychiatric hospitalization. WMM conceptualizes how stigma is felt most acutely when people are unable to achieve 'full personhood' by participating in the activities that 'matter most' in their local context.
In prior research, we found the core value for 'full womanhood' in Botswana is achieved by being the 'foundation of the household' and is threatened by perceived: 1) incompetence in fulfilling the duties of a family caregiver associated with SMI and 2) promiscuity associated with having HIV. In Botswana, family acceptance as a viable 'family caregiver' is also key to achieving 'full status' as a woman. As such, the risks of being identified as having SMI and HIV (e.g., partner/family abandonment) can deter psychiatric and ART treatment adherence.
Promoting capabilities that 'matter most' for achieving 'full womanhood' could enable longer-term stigma reduction after psychiatric discharge, when women are reintegrating into their communities, and improve ART adherence and promote sustained VL suppression.
Our group-based WMM stigma intervention is co-led by a peer woman who has coped effectively with SMI and HIV stigma. The WMM stigma intervention model was piloted among pregnant women with HIV in Botswana with promising reductions in stigma and depressive symptoms up to 4-months postpartum. We now test whether a WMM intervention tailored for women with SMI and HIV will reduce intersectional stigma and facilitate VL suppression.
We propose a two-arm randomized controlled trial (RCT; N=180) with a 4-month follow-up to compare the effectiveness of 1) WMM-based intersectional stigma intervention delivered as clients transition from psychiatric hospitalization to outpatient care ('WMM Stigma Intervention;' N=90); and 2) attention control following a similar format to isolate the effects of the intervention (N=90).
Because family are commonly involved in the care of people with SMI and face severe stigma, we propose a parallel, group stigma intervention among family members, as addressing familial stigma could facilitate treatment adherence.
Finally, because intersectional stigma is reinforced at systemic levels, we seek to empower women with SMI and HIV to influence structural change by co-leading policymaker workshops to reduce stigma among policymakers and spur policymakers to address the unique needs of women with SMI and HIV via future policies.
Reducing stigma to ensure viral load (VL) suppression for women with serious mental illness (SMI) and HIV is a global priority, including in Botswana, where the intersectional stigma of SMI, HIV, and womanhood is marginalizing in ways that impede adherence to both psychiatric medications and antiretroviral therapy (ART), which can threaten VL suppression.
We apply our novel 'What Matters Most' (WMM) approach to target intersectional stigma faced by women with SMI and HIV in Botswana via a stigma-reduction intervention in the high-risk transition period after discharge from an initial psychiatric hospitalization. WMM conceptualizes how stigma is felt most acutely when people are unable to achieve 'full personhood' by participating in the activities that 'matter most' in their local context.
In prior research, we found the core value for 'full womanhood' in Botswana is achieved by being the 'foundation of the household' and is threatened by perceived: 1) incompetence in fulfilling the duties of a family caregiver associated with SMI and 2) promiscuity associated with having HIV. In Botswana, family acceptance as a viable 'family caregiver' is also key to achieving 'full status' as a woman. As such, the risks of being identified as having SMI and HIV (e.g., partner/family abandonment) can deter psychiatric and ART treatment adherence.
Promoting capabilities that 'matter most' for achieving 'full womanhood' could enable longer-term stigma reduction after psychiatric discharge, when women are reintegrating into their communities, and improve ART adherence and promote sustained VL suppression.
Our group-based WMM stigma intervention is co-led by a peer woman who has coped effectively with SMI and HIV stigma. The WMM stigma intervention model was piloted among pregnant women with HIV in Botswana with promising reductions in stigma and depressive symptoms up to 4-months postpartum. We now test whether a WMM intervention tailored for women with SMI and HIV will reduce intersectional stigma and facilitate VL suppression.
We propose a two-arm randomized controlled trial (RCT; N=180) with a 4-month follow-up to compare the effectiveness of 1) WMM-based intersectional stigma intervention delivered as clients transition from psychiatric hospitalization to outpatient care ('WMM Stigma Intervention;' N=90); and 2) attention control following a similar format to isolate the effects of the intervention (N=90).
Because family are commonly involved in the care of people with SMI and face severe stigma, we propose a parallel, group stigma intervention among family members, as addressing familial stigma could facilitate treatment adherence.
Finally, because intersectional stigma is reinforced at systemic levels, we seek to empower women with SMI and HIV to influence structural change by co-leading policymaker workshops to reduce stigma among policymakers and spur policymakers to address the unique needs of women with SMI and HIV via future policies.
Awardee
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding Agency
Funding Agency
Place of Performance
New York,
New York
100122338
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 301% from $194,299 to $778,680.
New York University was awarded
Intersectional Stigma Intervention Women with SMI HIV in Botswana
Project Grant R01TW012402
worth $778,680
from the National Institute of Mental Health in July 2022 with work to be completed primarily in New York New York United States.
The grant
has a duration of 3 years and
was awarded through assistance program 93.242 Mental Health Research Grants.
The Project Grant was awarded through grant opportunity Interventions for Stigma Reduction to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle- Income Countries (R01 - Clinical Trial Optional).
Status
(Complete)
Last Modified 8/20/24
Period of Performance
7/1/22
Start Date
6/30/25
End Date
Funding Split
$778.7K
Federal Obligation
$0.0
Non-Federal Obligation
$778.7K
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for R01TW012402
Transaction History
Modifications to R01TW012402
Additional Detail
Award ID FAIN
R01TW012402
SAI Number
R01TW012402-377827786
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Private Institution Of Higher Education
Awarding Office
75NF00 NIH FOGARTY INTERNATIONAL CENTER
Funding Office
75N700 NIH NATIONAL INSTITUTE OF MENTAL HEALTH
Awardee UEI
NX9PXMKW5KW8
Awardee CAGE
72061
Performance District
NY-10
Senators
Kirsten Gillibrand
Charles Schumer
Charles Schumer
Budget Funding
Federal Account | Budget Subfunction | Object Class | Total | Percentage |
---|---|---|---|---|
John E. Fogarty International Center, National Institutes of Health, Health and Human Services (075-0819) | Health research and training | Grants, subsidies, and contributions (41.0) | $235,846 | 52% |
National Institute of Mental Health, National Institutes of Health, Health and Human Services (075-0892) | Health research and training | Grants, subsidies, and contributions (41.0) | $150,000 | 33% |
National Institute of Nursing Research, National Institutes of Health, Health and Human Services (075-0889) | Health research and training | Grants, subsidies, and contributions (41.0) | $63,828 | 14% |
Modified: 8/20/24